The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Oncolytic Adenovirus Market Grow Between 2026 And 2030?
The oncolytic adenovirus market has demonstrated robust expansion over recent years. Its valuation is set to climb from $132.49 billion in 2025 to $143.57 billion in 2026, with a compound annual growth rate (CAGR) of 8.4%. This historical growth can be linked to the progression of first-generation adenovirus-based therapies, the rising incidence of melanoma and prostate cancer, increased funding for oncolytic virus research, initial implementation by cancer research institutes, and enhanced partnerships between biotechnology firms and academic entities.
The oncolytic adenovirus market is anticipated to experience substantial growth over the coming years, with projections indicating an expansion to $195.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This projected increase is driven by factors such as the escalating demand for engineered adenovirus therapies, their increased use in treating breast, ovarian, and lung cancers, a rise in biotechnology company involvement, greater funding for clinical trials and research and development efforts, and the enhanced capabilities of hospitals and research institutes in gene therapy. Key trends influencing the market during this forecast period include the expanding integration of AI and big data in oncolytic virus research, the growing application of genomics and precision medicine in virus engineering, an increased reliance on digital platforms for overseeing clinical trials, heightened automation in viral production and quality control, and the deployment of IoT-enabled systems for monitoring virus storage and distribution.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp
What Significant Factors Are Influencing The Oncolytic Adenovirus Market Expansion?
The growing occurrence of cancer is projected to drive expansion within the oncolytic adenovirus market in the future. Cancer is defined as an illness marked by unchecked cell proliferation and its dissemination throughout the body. This rising prevalence of cancer stems from factors such as aging demographics, lifestyle choices, exposure to environmental elements, genetic susceptibilities, and enhanced diagnostic capabilities. Oncolytic adenovirus specifically targets and eliminates cancer cells, presenting a promising method for addressing the escalating rates of cancer. For example, reports from the US government’s National Cancer Institute (NCI) in May 2024 indicated almost 20 million new cancer cases and 9.7 million global deaths, with forecasts predicting an increase to 29.9 million cases and 15.3 million deaths by 2040. Moreover, data from the Australian Bureau of Statistics in 2023 showed that 1.8% of Australians suffered from cancer, with males (2.1%) being marginally more impacted than females (1.6%), particularly among individuals aged 75 and over. Consequently, the increasing incidence of cancer is stimulating growth in the oncolytic adenovirus market.
Which Segment Categories Are Included In The Oncolytic Adenovirus Market Segment Analysis?
The oncolytic adenovirus market covered in this report is segmented –
1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types
2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications
3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes
Subsegments:
1) By Adenovirus Type 5-Based Oncolytic Viruses: First-Generation Adenovirus Type 5-Based, Second-Generation Adenovirus Type 5-Based, Engineered Adenovirus Type 5-Based
2) By Adenovirus Type 2-Based Oncolytic Viruses: First-Generation Adenovirus Type 2-Based, Second-Generation Adenovirus Type 2-Based, Engineered Adenovirus Type 2-Based
3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses
What Trends Are Affecting The Direction Of The Oncolytic Adenovirus Market?
Major companies within the oncolytic adenovirus market are prioritizing combination therapies, such as VCN-01, which merges oncolytic virotherapy with chemotherapy to improve tumor targeting and therapeutic outcomes. VCN-01 is an oncolytic adenovirus crafted to selectively infect and eliminate cancer cells, simultaneously bolstering the efficacy of chemotherapy. For instance, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology company, revealed that the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation (FTD) to its lead candidate, VCN-01. This designation applies to VCN-01 when administered in combination with gemcitabine and nab-paclitaxel for treating metastatic pancreatic adenocarcinoma. VCN-01 functions as an oncolytic adenovirus that targets and replicates within tumor cells, assisting in the degradation of the tumor stroma, a significant impediment to effective cancer treatment.
Who Are The Active Companies Shaping The Oncolytic Adenovirus Market?
Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.
Get The Full Oncolytic Adenovirus Market Report:
https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report
Which Region Leads The Oncolytic Adenovirus Market In Terms Of Market Share?
North America was the largest region in the oncolytic adenovirus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Oncolytic Adenovirus Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report
Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2026, By The Business Research Company
Companion Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report
Cancer Diagnostics Market Report
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Clinical Diagnostics Market Report
https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model